共 50 条
- [21] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialLANCET INFECTIOUS DISEASES, 2022, 22 (02): : 209 - 221Ader, FlorenceBouscambert-Duchamp, MaudeHites, MayaPeiffer-Smadja, NathanPoissy, JulienBelhadi, DrifaDiallo, AlphaLe, Minh-PatrickPeytavin, GillesStaub, ThereseGreil, RichardGuedj, JeremiePaiva, Jose-ArturCostagliola, DominiqueYazdanpanah, YazdanBurdet, CharlesMentre, France
- [22] Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2022, 23 (04): : 465 - 478Kristeleit, RebeccaLisyanskaya, AllaFedenko, AlexanderDvorkin, Mikhailde Melo, Andreia CristinaShparyk, YaroslavRakhmatullina, IrinaBondarenko, IgorColombo, NicolettaSvintsitskiy, ValentynBiela, LucianoNechaeva, MarinaLorusso, DomenicaScambia, GiovanniCibula, DavidPoka, RobertOaknin, AnaSafra, TamarMackowiak-Matejczyk, BeataMa, LingThomas, DaleenLin, Kevin K.McLachlan, KarenGoble, SandraOza, Amit M.
- [23] monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+advanced breast cancerANNALS OF ONCOLOGY, 2016, 27Tolaney, S. M.Bourayou, N.Goel, S.Forrester, T.Andre, F.
- [24] A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Abu-Khalaf, Maysa M.Mayer, Ingrid A.Tankersley, ChrisMoy, JadineAllen, Andrew R.Vogel, Charles L.Holmes, Frankie AnnNanda, RitaMiller, KathyPatel, RavindranathPusztai, LajosArteaga, Carlos L.
- [25] Erratum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerBritish Journal of Cancer, 2016, 115 : e16 - e16Angus G DalgleishJustin StebbingDouglas J A AdamsonSeema Safia ArifPaolo BidoliDavid ChangSue CheesemanRobert Diaz-BeveridgeCarlos Fernandez-MartosRob Glynne-JonesCristina GranettoBartomeu MassutiKaren McAdamRaymond McDermottAndrés J Muñoz MartínDemetris PapamichaelRoberto Pazo-CidJose M VieitezAlberto ZaniboniKevin J CarrollShama WagleAndrew GayaSatvinder S Mudan
- [26] Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UKTACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trialLANCET ONCOLOGY, 2017, 18 (07): : 929 - 945Cameron, DavidMorden, James P.Canney, PeterVelikova, GalinaColeman, RobertBartlett, JohnAgrawal, RajivBanerji, JaneBertelli, GianfilippoBloomfield, DavidBrunt, A. MurrayEarl, HelenaEllis, PaulGaunt, ClaireGillman, AlexaHearfield, NicholasLaing, RobertMurray, NicholasCouper, NikiStein, Robert C.Verrill, MarkWardley, AndrewBarrett-Lee, PeterBliss, Judith M.
- [27] Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 studyLANCET ONCOLOGY, 2015, 16 (04): : 406 - 416Kawai, AkiraAraki, NobuhitoSugiura, HideshiUeda, TakafumiYonemoto, TsukasaTakahashi, MitsuruMorioka, HideoHiraga, HiroakiHiruma, ToruKunisada, ToshiyukiMatsumine, AkihikoTanase, TakanoriHasegawa, TadashiTakahashi, Shunji
- [28] Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial (vol 21, pg 763, 2020)LANCET ONCOLOGY, 2021, 22 (03): : E92 - E92Tolaney, S. M.Wardley, A. M.Zambelli, S.
- [29] Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trialBMC CANCER, 2020, 20 (01)Lieverse, Relinde I. Y.Van Limbergen, Evert J.Oberije, Cary J. G.Troost, Esther G. C.Hadrup, Sine R.Dingemans, Anne-Marie C.Hendriks, Lizza E. L.Eckert, FranziskaHiley, CrispinDooms, ChristopheLievens, Yolandede Jong, Monique C.Bussink, JohanGeets, XavierValentini, VincenzoElia, GiulianoNeri, DarioBilliet, CharlotteAbdollahi, AmirPasquier, DavidBoisselier, PierreYaromina, AlaDe Ruysscher, DirkDubois, Ludwig J.Lambin, Philippe
- [30] Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trialBMC Cancer, 20Relinde I. Y. LieverseEvert J. Van LimbergenCary J. G. OberijeEsther G. C. TroostSine R. HadrupAnne-Marie C. DingemansLizza E. L. HendriksFranziska EckertCrispin HileyChristophe DoomsYolande LievensMonique C. de JongJohan BussinkXavier GeetsVincenzo ValentiniGiuliano EliaDario NeriCharlotte BillietAmir AbdollahiDavid PasquierPierre BoisselierAla YarominaDirk De RuysscherLudwig J. DuboisPhilippe Lambin